Benzinga | Jun 9, 2021 06:14AM EDT

Innate Pharma To Present Data From Tellomak Trial At 16th International Conference on Malignant Lymphoma Jun. 22

Innate Pharma SA (OTC:IPHYF, NASDAQ:IPHA) ("Innate" or the "Company") today announced that preliminary mycosis fungoides data from the Phase 2 TELLOMAK trial evaluating lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas, will be presented during an oral presentation at the virtual 16th International Conference on Malignant Lymphoma (16-ICML) taking place from June 18-22, 2021.



Oral presentation details:Title: Lacutamab in patients with advanced mycosis fungoides according toKIR3DL2 expression: early results from the TELLOMAK phase 2 trialDate and time: June 22, 2021 at 1 p.m. CESTAbstract number: 054

TELLOMAK trial investigator, Martine Bagot, M.D., Ph.D., Professor of Dermatology, Head of the Dermatology Department at the Saint-Louis Hospital, University of Paris, will deliver the oral presentation.



Pr. Bagot will also present the data during an Innate Pharma online webcast for the financial community on June 23, 2021. Details about this webcast will be provided on the Company website by June 16, 2021.